Makes aXess, a restorative vascular access conduit for hemodialysis that the body gradually replaces with its own tissue. Commercial in Europe since July 2026 and running a US pivotal trial.
One email, every morning
THE MORNING BRIEF
New clearances, funding rounds and regulatory moves for device founders, and every new how-to guide and template as it lands. No noise, no login.
✓
You're in. The next morning brief lands in your inbox.
No Spam. Unsubscribe anytime.